Bioline Rx Ltd
Research Bioline Rx Ltd (BLRX) on Bullrun: market cap USD 12.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBLRX
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.40M
- Financial periodQ1 2026
- RevenueUSD 477.00K
- Net income-USD 1.60M
- Free cash flow-USD 2.29M
- Gross margin80.1%
Valuation Snapshot
latest market cap is USD 12.40M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.18M | -USD 1.18M | -USD 8.10M | 80.5% | 0 | USD 3.25M | USD 10.15M | USD 18.20M |
| FY2024 | USD 28.94M | -USD 9.22M | -USD 43.93M | 68.0% | n/a | USD 10.44M | USD 15.04M | USD 13.46M |
| FY2023 | n/a | n/a | n/a | n/a | -1.65 | USD 4.26M | USD 11.59M | USD 13.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.40M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 113.73M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.30M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 97.26M | n/a | n/a | n/a |
About Bioline Rx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bioline Rx Ltd's market cap?
Bioline Rx Ltd's market capitalization is USD 12.40M.
What does Bioline Rx Ltd do?
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.